PARP inhibitors in prostate cancer: clinical applications.
Humans
Poly(ADP-ribose) Polymerase Inhibitors
/ therapeutic use
Male
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Prostatic Neoplasms
/ drug therapy
Phthalazines
/ therapeutic use
Piperazines
/ therapeutic use
Drug Resistance, Neoplasm
/ genetics
Antineoplastic Agents
/ therapeutic use
Indoles
/ therapeutic use
Recombinational DNA Repair
/ drug effects
Homologous recombination repair
PARP inhibition
Prostate cancer
Targeted therapy
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
09
08
2024
accepted:
17
10
2024
medline:
31
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Despite recent advancements in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), this disease remains lethal. A novel family of targeted pharmaceuticals known as poly-ADP-ribose polymerase (PARP) inhibitors has been developed to treat mCRPC patients with homologous recombination repair (HRR) gene alterations. The FDA recently approved olaparib and rucaparib for treating mCRPC patients with HRR gene alterations. Ongoing trials are investigating combination therapies involving PARP inhibitors combined with radiation, chemotherapy, immunotherapy, and androgen receptor signaling inhibitors (ARSIs) to improve the effectiveness of PARP inhibitors and broaden the range of patients who can benefit from the treatment. This review provides an overview of the development of PARP inhibitors in prostate cancer and analyzes the mechanisms underlying their resistance.
Identifiants
pubmed: 39476131
doi: 10.1007/s11033-024-10034-5
pii: 10.1007/s11033-024-10034-5
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Phthalazines
0
Piperazines
0
olaparib
WOH1JD9AR8
rucaparib
8237F3U7EH
Antineoplastic Agents
0
Indoles
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1103Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Siegel RL, Giaquinto AN, Jemal A, Cancer statistics (2024) CA Cancer J Clin. 2024; 74(1): 12–49. https://doi.org/10.3322/caac.21820 . Epub 2024 Jan 17. PMID: 38230766
Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L et al (2023) Castration-resistant prostate Cancer: from uncovered resistance mechanisms to current treatments. Cancers (Basel) 15(20):5047. https://doi.org/10.3390/cancers15205047 . PMID: 37894414; PMCID: PMC10605314
doi: 10.3390/cancers15205047
pubmed: 37894414
Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R et al (2021) PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res 40(1):211. https://doi.org/10.1186/s13046-021-02005-6 . PMID: 34167572; PMCID: PMC8228511
doi: 10.1186/s13046-021-02005-6
pubmed: 34167572
Li J, Li Q, Zhang L, Zhang S, Dai Y (2023) Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function. Biomed Pharmacother 157:114028. https://doi.org/10.1016/j.biopha.2022.114028 . Epub 2022 Nov 18. PMID: 36410122
doi: 10.1016/j.biopha.2022.114028
pubmed: 36410122
Kanev PB, Atemin A, Stoynov S, Aleksandrov R (2024) PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistance. Semin Oncol 51(1–2):2–18. https://doi.org/10.1053/j.seminoncol.2023.08.001 . Epub 2023 Sep 6. PMID: 37714792
doi: 10.1053/j.seminoncol.2023.08.001
pubmed: 37714792
Kim DS, Camacho CV, Kraus WL (2021) Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 53(1):42–51. https://doi.org/10.1038/s12276-021-00557-3 . Epub 2021 Jan 25. PMID: 33487630; PMCID: PMC8080675
doi: 10.1038/s12276-021-00557-3
pubmed: 33487630
Nambiar DK, Mishra D, Singh RP (2023) Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials. Oncol Res 31(4):405–421. https://doi.org/10.32604/or.2023.028310 . PMID: 37415740; PMCID: PMC10319588
doi: 10.32604/or.2023.028310
pubmed: 37415740
Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast Cancer. Target Oncol 16(3):255–282. https://doi.org/10.1007/s11523-021-00796-4 . Epub 2021 Mar 12. PMID: 33710534; PMCID: PMC8105250
doi: 10.1007/s11523-021-00796-4
pubmed: 33710534
Chatterjee N, Walker GC (2017) Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen 58(5):235–263. https://doi.org/10.1002/em.22087 . Epub 2017 May 9. PMID: 28485537; PMCID: PMC5474181
doi: 10.1002/em.22087
pubmed: 28485537
pmcid: 5474181
Lisby M, Rothstein R (2015) Cell biology of mitotic recombination. Cold Spring Harb Perspect Biol 7(3):a016535. https://doi.org/10.1101/cshperspect.a016535 . Epub: 25731763; PMCID: PMC4355273
doi: 10.1101/cshperspect.a016535
pubmed: 25731763
pmcid: 4355273
Li J, Sun H, Huang Y, Wang Y, Liu Y, Chen X (2019) Pathways and assays for DNA double-strand break repair by homologous recombination. Acta Biochim Biophys Sin (Shanghai) 51(9):879–889. https://doi.org/10.1093/abbs/gmz076 . PMID: 31294447
Akhoundova D, Francica P, Rottenberg S, Rubin MA (2024) DNA damage response and mismatch repair gene defects in Advanced and metastatic prostate Cancer. Adv Anat Pathol 31(2):61–69. https://doi.org/10.1097/PAP.0000000000000422 . Epub 2023 Nov 27. PMID: 38008971; PMCID: PMC10846598
doi: 10.1097/PAP.0000000000000422
pubmed: 38008971
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H et al (2016) Inherited DNA-Repair gene mutations in men with metastatic prostate Cancer. N Engl J Med 375(5):443–453. https://doi.org/10.1056/NEJMoa1603144 . Epub 2016 Jul 6. PMID: 27433846; PMCID: PMC4986616
doi: 10.1056/NEJMoa1603144
pubmed: 27433846
pmcid: 4986616
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A 116(23):11428–11436. https://doi.org/10.1073/pnas.1902651116 . Epub 2019 May 6. PMID: 31061129; PMCID: PMC6561293
doi: 10.1073/pnas.1902651116
pubmed: 31061129
pmcid: 6561293
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228. https://doi.org/10.1016/j.cell.2015.05.001 . Erratum in: Cell. 2015; 162(2):454. PMID: 26000489; PMCID: PMC4484602
Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B et al (2024) NCCN Guidelines
Saeidi H, Bakrin IH, Raju CS, Ismail P, Saraf M, Khairul-Asri MG (2023) Genetic aberrations of homologous recombination repair pathways in prostate cancer: the prognostic and therapeutic implications. Adv Med Sci 68(2):359–365. https://doi.org/10.1016/j.advms.2023.09.008 Epub 2023 Sep 25. PMID: 37757663
doi: 10.1016/j.advms.2023.09.008
pubmed: 37757663
Zhang Z, Diao L, Zhang C, Wang F, Guan X, Yao X (2023) Use of PARP inhibitors in prostate cancer: from specific to broader application. Front Endocrinol (Lausanne) 14:1164067. https://doi.org/10.3389/fendo.2023.1164067 . Epub: 37152924; PMCID: PMC10162014
doi: 10.3389/fendo.2023.1164067
pubmed: 37152924
Kurnit KC, Coleman RL, Westin SN (2018) Using PARP inhibitors in the treatment of patients with ovarian Cancer. Curr Treat Options Oncol 19(12):1. https://doi.org/10.1007/s11864-018-0572-7 . Epub: 30535808; PMCID: PMC8240125
doi: 10.1007/s11864-018-0572-7
pubmed: 30535808
pmcid: 8240125
Wang Y, Luo W, Wang Y (2019) PARP-1 and its associated nucleases in DNA damage response. DNA Repair (Amst) 81:102651. https://doi.org/10.1016/j.dnarep.2019.102651 . Epub 2019 Jul 8. PMID: 31302005; PMCID: PMC6764844
doi: 10.1016/j.dnarep.2019.102651
pubmed: 31302005
Cerrato A, Morra F, Celetti A (2016) Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 35(1):179. https://doi.org/10.1186/s13046-016-0456-2 . Epub: 27884198; PMCID: PMC5123312
doi: 10.1186/s13046-016-0456-2
pubmed: 27884198
pmcid: 5123312
Klotz DM, Wimberger P (2020) Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? Arch Gynecol Obstet 302(5):1087–1102. 1007/s00404-020-05677-1. Epub 2020 Aug 24. PMID: 32833070; PMCID: PMC7524817
doi: 10.1007/s00404-020-05677-1
pubmed: 32833070
pmcid: 7524817
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599. https://doi.org/10.1158/0008-5472.CAN-12-2753 . Epub: 23118055; PMCID: PMC3528345
doi: 10.1158/0008-5472.CAN-12-2753
pubmed: 23118055
pmcid: 3528345
Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S et al (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2):433–443. https://doi.org/10.1158/1535-7163.MCT-13-0803 . Epub 2013 Dec 19. PMID: 24356813; PMCID: PMC3946062
doi: 10.1158/1535-7163.MCT-13-0803
pubmed: 24356813
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al (2015) DNA-Repair defects and Olaparib in metastatic prostate Cancer. N Engl J Med 373(18):1697–1708. https://doi.org/10.1056/NEJMoa1506859 . Epub: 26510020; PMCID: PMC5228595
doi: 10.1056/NEJMoa1506859
pubmed: 26510020
pmcid: 5228595
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R et al (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(1):162–174 Epub 2019 Dec 2. PMID: 31806540; PMCID: PMC6941219
doi: 10.1016/S1470-2045(19)30684-9
pubmed: 31806540
pmcid: 6941219
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for metastatic castration-resistant prostate Cancer. N Engl J Med 382(22):2091–2102. https://doi.org/10.1056/NEJMoa1911440 . Epub 2020 Apr 28. PMID: 32343890
doi: 10.1056/NEJMoa1911440
pubmed: 32343890
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Survival with Olaparib in Metastatic Castration-resistant prostate Cancer. N Engl J Med 383(24):2345–2357. https://doi.org/10.1056/NEJMoa2022485 . Epub 2020 Sep 20. PMID: 32955174
doi: 10.1056/NEJMoa2022485
pubmed: 32955174
Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S et al (2024) Olaparib for the treatment of patients with metastatic castration-resistant prostate Cancer and alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol 42(5):571–583. https://doi.org/10.1200/JCO.23.00339 . Epub 2023 Nov 14. PMID: 37963304
doi: 10.1200/JCO.23.00339
pubmed: 37963304
Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R et al (2020) Rucaparib in Men with metastatic castration-resistant prostate Cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38(32):3763–3772. https://doi.org/10.1200/JCO.20.01035 . Epub 2020 Aug 14. PMID: 32795228; PMCID: PMC7655021
doi: 10.1200/JCO.20.01035
pubmed: 32795228
Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ et al (2020) Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate Cancer: analysis from the phase II TRITON2 study. Clin Cancer Res 26(11):2487–2496. https://doi.org/10.1158/1078-0432.CCR-20-0394 . Epub 2020 Feb 21. PMID: 32086346; PMCID: PMC8435354
doi: 10.1158/1078-0432.CCR-20-0394
pubmed: 32086346
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR et al (2023) Rucaparib or Physician’s choice in metastatic prostate Cancer. N Engl J Med 388(8):719–732. https://doi.org/10.1056/NEJMoa2214676 . Epub 2023 Feb 16. PMID: 36795891; PMCID: PMC10064172
doi: 10.1056/NEJMoa2214676
pubmed: 36795891
Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S et al (2024) A phase II study of Rucaparib Monotherapy in Nonmetastatic, hormone-sensitive prostate Cancer demonstrating BRCAness genotype (ROAR). Oncologist 29(5):450–e725. https://doi.org/10.1093/oncolo/oyae030 . Epub: 38452035; PMCID: PMC11067793
doi: 10.1093/oncolo/oyae030
pubmed: 38452035
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY et al (2022) Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol 23(3):362–373. https://doi.org/10.1016/S1470-2045(21)00757-9 . Epub 2022 Feb 4. PMID: 35131040; PMCID: PMC9361481
doi: 10.1016/S1470-2045(21)00757-9
pubmed: 35131040
pmcid: 9361481
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A et al (2021) Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. ; 22(9):1250–1264. https://doi.org/10.1016/S1470-2045(21)00376-4 . Epub 2021 Aug 10. Erratum in: Lancet Oncol. 2022;23(5):e207. Erratum in: Lancet Oncol. 2022;23(6):e249. PMID: 34388386
Soung YH, Chung J (2023) Combination treatment strategies to overcome PARP inhibitor resistance. Biomolecules 13(10):1480. https://doi.org/10.3390/biom13101480 . Epub: 37892162; PMCID: PMC10604269
doi: 10.3390/biom13101480
pubmed: 37892162
pmcid: 10604269
Agarwal N, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F et al (2023) The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer 192:113249. https://doi.org/10.1016/j.ejca.2023.113249 . Epub 2023 Jul 23. PMID: 37672815
doi: 10.1016/j.ejca.2023.113249
pubmed: 37672815
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D et al (2023) Niraparib and Abiraterone acetate for metastatic castration-resistant prostate Cancer. J Clin Oncol 41(18):3339–3351. https://doi.org/10.1200/JCO.22.01649 . Epub 2023 Mar 23. PMID: 36952634; PMCID: PMC10431499
doi: 10.1200/JCO.22.01649
pubmed: 36952634
pmcid: 10431499
Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Loredo E, Procopio G et al (2022) PROpel: Phase III Trial of Olaparib (ola) and abiraterone (Abi) versus placebo (pbo) and Abi as First-Line (1L) therapy for patients (pts) with metastatic castration-resistant prostate Cancer (MCRPC). J Clin Oncol 40:11
doi: 10.1200/JCO.2022.40.6_suppl.011
Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroğlu M, Gedye C et al. (2024) Tolerability of Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3 PROpel trial. Eur Urol Oncol S2588-9311(24):00082 – 8. https://doi.org/10.1016/j.euo.2024.03.006 . Epub ahead of print. PMID: 38582650
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D et al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402(10398):291–303. https://doi.org/10.1016/S0140-6736(23)01055-3 . Epub 2023 Jun 4. Erratum in: Lancet. 2023;402(10398):290. PMID: 37285865
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U et al (2024) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. ; 30(1):257–264. https://doi.org/10.1038/s41591-023-02704-x . Epub 2023 Dec 4. Erratum in: Nat Med. 2024;: PMID: 38049622; PMCID: PMC10803259
Choi HY, Chang JE (2023) Targeted therapy for cancers: from ongoing clinical trials to FDA-Approved drugs. Int J Mol Sci 24(17):13618. https://doi.org/10.3390/ijms241713618 . Epub: 37686423; PMCID: PMC10487969
doi: 10.3390/ijms241713618
pubmed: 37686423
pmcid: 10487969
Chen X, Pan Y, Wang Q, Ren C, Li M, Hao X et al (2023) Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer. Front Endocrinol (Lausanne) 14:1225033. https://doi.org/10.3389/fendo.2023.1225033 . Epub: 38027160; PMCID: PMC10644304
doi: 10.3389/fendo.2023.1225033
pubmed: 38027160
Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q et al (2024) Olaparib Combined with Abiraterone versus Olaparib Monotherapy for patients with metastatic castration-resistant prostate Cancer progressing after Abiraterone and harboring DNA damage Repair Deficiency: a Multicenter Real-world study. Eur Urol Oncol S2588–9311(24 00050–6). https://doi.org/10.1016/j.euo.2024.02.005 . Epub ahead of print. PMID: 38458891
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ et al Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Aug 8. https://doi.org/10.1158/1078-0432.CCR-24-1402 . Epub ahead of print. PMID: 39115414
Piulats JM, Azad AA, Laird AD, Matsubara N, Fizazi K, Shore ND et al (2024) TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT018
Heiss BL, Chang E, Gao X, Truong T, Brave MH, Bloomquist E et al (2024) US Food and Drug Administration approval Summary: Talazoparib in Combination with Enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. J Clin Oncol 42(15):1851–1860. https://doi.org/10.1200/JCO.23.02182 . Epub 2024 Mar 7. PMID: 38452327; PMCID: PMC11095902
doi: 10.1200/JCO.23.02182
pubmed: 38452327
Wang Y, Zheng K, Xiong H, Huang Y, Chen X, Zhou Y et al (2021) PARP inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer. Front Immunol 12:762989. https://doi.org/10.3389/fimmu.2021.762989 . Epub: 34975854; PMCID: PMC8718453
doi: 10.3389/fimmu.2021.762989
pubmed: 34975854
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM et al (2017) PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23(14):3711–3720. https://doi.org/10.1158/1078-0432.CCR-16-3215 . Epub 2017 Feb 6. PMID: 28167507; PMCID: PMC5511572
doi: 10.1158/1078-0432.CCR-16-3215
pubmed: 28167507
pmcid: 5511572
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A et al (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 6(1):141. https://doi.org/10.1186/s40425-018-0463-2 . Epub: 30514390; PMCID: PMC6280368
doi: 10.1186/s40425-018-0463-2
pubmed: 30514390
pmcid: 6280368
Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B et al (2023) Pembrolizumab plus Olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort a study. Eur Urol 83(1):15–26. https://doi.org/10.1016/j.eururo.2022.08.005 . Epub 2022 Aug 30. Erratum in: Eur Urol. 2023;83(3):e87. PMID: 36055895
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N et al (2023) Pembrolizumab Plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate Cancer: the randomized, Open-Label, phase III KEYLYNK-010 trial. J Clin Oncol 41(22):3839–3850. https://doi.org/10.1200/JCO.23.00233 . Epub 2023 Jun 8. PMID: 37290035; PMCID: PMC10419579
doi: 10.1200/JCO.23.00233
pubmed: 37290035
pmcid: 10419579
Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L et al (2022) Nivolumab plus Rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer 10(8):e004761. https://doi.org/10.1136/jitc-2022-004761 . Epub: 35977756; PMCID: PMC9389086
doi: 10.1136/jitc-2022-004761
pubmed: 35977756
pmcid: 9389086
Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM et al (2014) Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 32(5):904–912. https://doi.org/10.1007/s10637-014-0099-0 . Epub 2014 Apr 26. PMID: 24764124; PMCID: PMC4659356
doi: 10.1007/s10637-014-0099-0
pubmed: 24764124
pmcid: 4659356
Sun C, Chu A, Song R, Liu S, Chai T, Wang X et al (2023) PARP inhibitors combined with radiotherapy: are we ready? Front Pharmacol 14:1234973. https://doi.org/10.3389/fphar.2023.1234973 . Epub: 37954854; PMCID: PMC10637512
doi: 10.3389/fphar.2023.1234973
pubmed: 37954854
pmcid: 10637512
Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D et al (2023) Phase I study of Niraparib in Combination with Radium-223 for the treatment of metastatic castrate-resistant prostate Cancer. Clin Cancer Res 29(1):50–59. https://doi.org/10.1158/1078-0432.CCR-22-2526 . Epub: 36321991; PMCID: PMC9812873
doi: 10.1158/1078-0432.CCR-22-2526
pubmed: 36321991
pmcid: 9812873
Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E et al (2023) A phase I study of combination olaparib and Radium-223 in men with metastatic castration-resistant prostate Cancer (mCRPC) with bone metastases (COMRADE). Mol Cancer Ther 22(4):511–518. https://doi.org/10.1158/1535-7163.MCT-22-0583 . Epub: 36780008; PMCID: PMC10769512
doi: 10.1158/1535-7163.MCT-22-0583
pubmed: 36780008
pmcid: 10769512
Leslie AR, Ning S, Armstrong CM, D’Abronzo LS, Sharifi M, Schaaf ZA et al (2024) IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience 27(2):108984. https://doi.org/10.1016/j.isci.2024.108984 . Epub: 38327800; PMCID: PMC10847745
doi: 10.1016/j.isci.2024.108984
pubmed: 38327800
pmcid: 10847745
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB et al (2023) Randomized Trial of Olaparib with or without Cediranib for metastatic castration-resistant prostate Cancer: the results from National Cancer Institute 9984. J Clin Oncol 41(4):871–880. https://doi.org/10.1200/JCO.21.02947 . Epub 2022 Oct 18. PMID: 36256912; PMCID: PMC9901975
doi: 10.1200/JCO.21.02947
pubmed: 36256912
Zhou S, Dai Z, Wang L, Gao X, Yang L, Wang Z et al (2021) MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. J Cell Mol Med 25(24):11157–11169. https://doi.org/10.1111/jcmm.17037 . Epub 2021 Nov 10. PMID: 34761497; PMCID: PMC8650038
doi: 10.1111/jcmm.17037
pubmed: 34761497
pmcid: 8650038
Reichert ZR, Devitt ME, Alumkal JJ, Smith DC, Caram MV, Palmbos P et al (2022) Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). J Clin Oncol 40(6suppl):88. https://doi.org/10.1200/JCO.2022.40.6_suppl.088
doi: 10.1200/JCO.2022.40.6_suppl.088
Pook D, Geynisman DM, Carles J, de Braud F, Joshua AM, Pérez-Gracia JL et al (2023) A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 29(17): 3292–3300. https://doi.org/10.1158/1078-0432.CCR-22-2585 . PMID: 37339186
Haynes B, Murai J, Lee JM (2018) Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev 71:1–7. https://doi.org/10.1016/j.ctrv.2018.09.003 . Epub 2018 Sep 11. PMID: 30269007; PMCID: PMC7429716
doi: 10.1016/j.ctrv.2018.09.003
pubmed: 30269007
pmcid: 7429716
Slade D (2020) PARP and PARG inhibitors in cancer treatment. Genes Dev 34(5–6):360–394. https://doi.org/10.1101/gad.334516.119 . Epub 2020 Feb 6. PMID: 32029455; PMCID: PMC7050487
doi: 10.1101/gad.334516.119
pubmed: 32029455
pmcid: 7050487
Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A et al (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141(2):243–254. https://doi.org/10.1016/j.cell.2010.03.012 . Epub 2010 Apr 1. PMID: 20362325; PMCID: PMC2857570
doi: 10.1016/j.cell.2010.03.012
pubmed: 20362325
pmcid: 2857570
Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK et al (2018) The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560(7716):117–121. https://doi.org/10.1038/s41586-018-0340-7 . Epub 2018 Jul 18. PMID: 30022168
Lei T, Du S, Peng Z, Chen L (2022) Multifaceted regulation and functions of 53BP1 in NHEJ–mediated DSB repair (review). Int J Mol Med 50(1):90. https://doi.org/10.3892/ijmm.2022.5145 . Epub 2022 May 18. PMID: 35583003; PMCID: PMC9162042
doi: 10.3892/ijmm.2022.5145
pubmed: 35583003
pmcid: 9162042
Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M et al (2018) DNA Repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity. Cell 173(4):972–988e23. https://doi.org/10.1016/j.cell.2018.03.050 . Epub 2018 Apr 12. PMID: 29656893; PMCID: PMC8108093.PMCID: PMC6141009
Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R et al (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19(11):1371–1378. https://doi.org/10.1038/ncb3626 . Epub 2017 Oct 16. PMID: 29035360
doi: 10.1038/ncb3626
pubmed: 29035360
Fu X, Li P, Zhou Q, He R, Wang G, Zhu S et al (2023) Mechanism of PARP inhibitor resistance and potential overcoming strategies. Genes Dis 11(1):306–320. https://doi.org/10.1016/j.gendis.2023.02.014 . Epub: 37588193; PMCID: PMC10425807
doi: 10.1016/j.gendis.2023.02.014
pubmed: 37588193
Jiang X, Li X, Li W, Bai H, Zhang Z (2019) PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms. J Cell Mol Med 23(4):2303–2313. https://doi.org/10.1111/jcmm.14133 . Epub 2019 Jan 22. PMID: 30672100; PMCID: PMC6433712
doi: 10.1111/jcmm.14133
pubmed: 30672100
Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19(1):107. https://doi.org/10.1186/s12943-020-01227-0 . Epub: 32563252; PMCID: PMC7305609
doi: 10.1186/s12943-020-01227-0
pubmed: 32563252
Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A et al (2023) Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate Cancer after treatment with Rucaparib. Eur Urol 83(3):200–209. https://doi.org/10.1016/j.eururo.2022.09.010 . Epub 2022 Oct 13. PMID: 36243543; PMCID: PMC10398818
doi: 10.1016/j.eururo.2022.09.010
pubmed: 36243543
Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S et al (2018) Acquired Resistance to Poly (ADP-ribose) polymerase inhibitor Olaparib in BRCA2-Associated prostate Cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations. JCO Precis Oncol2, 1-8. https://doi.org/10.1200/PO.17.00176
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105(44):17079–17084. https://doi.org/10.1073/pnas.0806092105 . Epub 2008 Oct 29. PMID: 18971340; PMCID: PMC2579381
doi: 10.1073/pnas.0806092105
pubmed: 18971340
Lombard AP, Liu C, Armstrong CM, D’Abronzo LS, Lou W, Chen H et al (2019) Overexpressed ABCB1 induces olaparib-taxane cross-resistance in advanced prostate cancer. Transl Oncol 12(7):871–878. https://doi.org/10.1016/j.tranon.2019.04.007 . Epub 2019 May 7. PMID: 31075528; PMCID: PMC6510951
doi: 10.1016/j.tranon.2019.04.007
pubmed: 31075528
Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN et al (2021) AMPLITUDE: a study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol 39:TPS176. https://doi.org/10.1200/JCO.2021.39.6_suppl.TPS176
doi: 10.1200/JCO.2021.39.6_suppl.TPS176
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND et al (2024) TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol 20(9):493–505. https://doi.org/10.2217/fon-2023-0526 . Epub 2023 Oct 26. PMID: 37882449
doi: 10.2217/fon-2023-0526
pubmed: 37882449
Rao A, Ryan CJ, VanderWeele DJ, Heller G, Lewis LD, Watt C, Chen RC, Grubb R, Hahn OM, Beltran H et al (2021) CASPAR (Alliance A031902): a randomized, phase III trialof enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 39:TPS181
doi: 10.1200/JCO.2021.39.6_suppl.TPS181